Corrigendum to “A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study” [J. Pharm. Biomed. Anal. 166 (2019) 20–29]
2020 ◽
Vol 181
◽
pp. 112627
2019 ◽
Vol 166
◽
pp. 20-29
2015 ◽
Vol 110
(4)
◽
pp. 543-550
◽
2013 ◽
Vol 935
◽
pp. 41-46
◽
2019 ◽
Vol 1117
◽
pp. 77-85
◽
2020 ◽
Vol 1611
◽
pp. 460598
◽